Clinical trial · Observational
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
NCT01472627CI-TRIAL-00031147completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draws | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Bortezomib treatment
- description
- Subjects receiving standard of care regimen including Bortezomib
- interventionNames
- Procedure: Blood draws
Primary outcomes (1)
- measure
- Effect of bortezomib on circulating dendritic cell and T cell populations
- timeFrame
- 2 years
- description
- Whether treatment with bortezomib reverses measures of tumor mediated immune suppression proving an improved platform for tumor specific immunotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed multiple myeloma * Therapy with bortezomib alone or bortezomib/dexamethasone being initiated as the standard of care therapy for myeloma by their treating physician Exclusion Criteria: * Hypersensitivity to bortezomib, boron or mannitol * Treatment with other investigational drugs within 28 days before enrollment * Diagnosed or treated for another malignancy within 6 months of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy * Use of other myeloma directed therapy (except for dexamethasone) in combination with bortezomib
References
Publications (0)
Data not yet available
No reference posted for this study.